Search

Your search keyword '"Tsamadou, Chrysanthi"' showing total 40 results
Start Over Author "Tsamadou, Chrysanthi"
40 results on '"Tsamadou, Chrysanthi"'

1. Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation

Author

Tsamadou, Chrysanthi, Gowdavally, Sowmya, Platzbecker, Uwe, Sala, Elisa, Valerius, Thomas, Wagner-Drouet, Eva, Wulf, Gerald, Kröger, Nicolaus, Murawski, Niels, Einsele, Hermann, Schaefer-Eckart, Kerstin, Freitag, Sebastian, Casper, Jochen, Kaufmann, Martin, Dürholt, Mareike, Hertenstein, Bernd, Klein, Stefan, Ringhoffer, Mark, Frank, Sandra, Neuchel, Christine, Rode, Immanuel, Schrezenmeier, Hubert, Mytilineos, Joannis, and Fuerst, Daniel

Published
2022
Full Text
View/download PDF

2. The impact of MICB mismatches in unrelated haematopoietic stem cell transplantation.

Author

Amann, Elisa Maria, Gowdavally, Sowmya, Tsamadou, Chrysanthi, Platzbecker, Uwe, Sala, Elisa, Wagner‐Drouet, Eva, Valerius, Thomas, Kröger, Nicolaus, Wulf, Gerald, Einsele, Hermann, Thurner, Lorenz, Schaefer‐Eckart, Kerstin, Freitag, Sebastian, Casper, Jochen, Dürholt, Mareike, Kaufmann, Martin, Hertenstein, Bernd, Klein, Stefan, Ringhoffer, Mark, and Frank, Sandra

Subjects
HEMATOPOIETIC stem cell transplantation, PROGRESSION-free survival, HLA histocompatibility antigens, DNA mismatch repair, LINKAGE disequilibrium
Abstract

MICA polymorphisms have been associated with increased incidence of acute GvHD and adverse outcome in allogeneic haematopoietic stem cell transplantation (HSCT). MICB is another expressed member of MHC class I‐related chain genes and its impact on HSCT outcome is yet to be fully defined. We typed a large cohort of patients and donors for MICB polymorphisms and investigated the impact of MICB matching on outcome after unrelated HSCT. 69.2% of the patients were 10/10 human leukocyte antigen (HLA) matched and 30.8% were 9/10 HLA matched. MICB typing was performed using a short amplicon‐based NGS typing assay on the Illumina MiSeq platform. Differences in proteins were considered as mismatches. MICA polymorphisms were identified as possible confounder and were therefore included as parameter in the multivariate analyses. Due to the strong linkage disequilibrium with the classical HLA‐genes, sub‐stratification for HLA matching status was necessary, and no effect of MICB mismatches was seen in the 10/10 HLA matched group when compared to the MICB matched cases. However, in the 9/10 HLA matched group, MICB mismatched cases showed significantly worse disease free survival (DFS), GvHD and relapse free survival (GRFS) compared to the MICB matched cases (DFS: HR 1.24, p = 0.011; GRFS: HR 1.26, p = 0.002). MICA mismatches had no impact on any outcome parameter. According to our findings, effects previously attributed to MICA differences may have been confounded by MICB polymorphisms. We show that MICB differences contribute a small but relevant effect in 9/10 HLA‐matched transplantations, which in turn highlights the possible usefulness of MICB typing in donor selection among similarly suitable 9/10 matched donors, especially when HLA‐B mismatches have to be accepted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. KIR2DS4 and Its Variant KIR1D in KIR-AA Genotype Donors Showed Differential Survival Impact in Patients with Lymphoid Disease after HLA-Matched Unrelated Hematopoietic Stem Cell Transplantation

Author

Gowdavally, Sowmya, Tsamadou, Chrysanthi, Platzbecker, Uwe, Sala, Elisa, Valerius, Thomas, Klein, Stefan, Kröger, Nicolaus, Wulf, Gerald, Einsele, Hermann, Thurner, Lorenz, Schaefer-Eckart, Kerstin, Freitag, Sebastian, Casper, Jochen, Dürholt, Mareike, Kaufmann, Martin, Hertenstein, Bernd, Ringhoffer, Mark, Schmeller, Sandra, Neuchel, Christine, Rode, Immanuel, Amann, Elisa Maria, Richter, Anita, Schrezenmeier, Hubert, Mytilineos, Joannis, and Fuerst, Daniel

Published
2023
Full Text
View/download PDF

5. Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation

Author

Fuerst, Daniel, Neuchel, Christine, Niederwieser, Dietger, Bunjes, Donald, Gramatzki, Martin, Wagner, Eva, Wulf, Gerald, Glass, Bertram, Pfreundschuh, Michael, Einsele, Hermann, Arnold, Renate, Stuhler, Gernot, Schaefer-Eckart, Kerstin, Freitag, Sebastian, Casper, Jochen, Kaufmann, Martin, Wattad, Mohammed, Hertenstein, Bernd, Klein, Stefan, Ringhoffer, Mark, Mytilineos, Daphne, Tsamadou, Chrysanthi, Mueller, Carlheinz, Schrezenmeier, Hubert, and Mytilineos, Joannis

Published
2016
Full Text
View/download PDF

6. Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations

Author

Tsamadou, Chrysanthi, primary, Ludwig, Carolin, additional, Scholz, Judith, additional, Proffen, Matthias, additional, Hägele, Janina, additional, Rode, Immanuel, additional, Körper, Sixten, additional, Fabricius, Dorit, additional, Jahrsdörfer, Bernd, additional, Neuchel, Christine, additional, Amann, Elisa, additional, Schrezenmeier, Hubert, additional, and Fürst, Daniel, additional

Published
2022
Full Text
View/download PDF

7. Higher risk for chronic graft‐versus‐host disease ( GvHD ) in HLA‐G mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective study

Author

Neuchel, Christine, primary, Gowdavally, Sowmya, additional, Tsamadou, Chrysanthi, additional, Platzbecker, Uwe, additional, Sala, Elisa, additional, Wagner‐Drouet, Eva, additional, Valerius, Thomas, additional, Kröger, Nicolaus, additional, Wulf, Gerald, additional, Einsele, Hermann, additional, Thurner, Lorenz, additional, Schaefer‐Eckart, Kerstin, additional, Freitag, Sebastian, additional, Casper, Jochen, additional, Dürholt, Mareike, additional, Kaufmann, Martin, additional, Hertenstein, Bernd, additional, Klein, Stefan, additional, Ringhoffer, Mark, additional, Frank, Sandra, additional, Amann, Elisa Maria, additional, Rode, Immanuel, additional, Schrezenmeier, Hubert, additional, Mytilineos, Joannis, additional, and Fürst, Daniel, additional

Published
2022
Full Text
View/download PDF

8. Higher risk for chronic graft-versus-host disease (GvHD) in HLA-G mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective study

Author

Neuchel, Christine, Gowdavally, Sowmya, Tsamadou, Chrysanthi, Platzbecker, Uwe, Sala, Elisa, Wagner-Drouet, Eva, Valerius, Thomas, Kröger, Nicolaus, Wulf, Gerald, Einsele, Hermann, Thurner, Lorenz, Schaefer-Eckart, Kerstin, Freitag, Sebastian, Casper, Jochen, Dürholt, Mareike, Kaufmann, Martin, Hertenstein, Bernd, Klein, Stefan, Ringhoffer, Mark, Frank, Sandra, Amann, Elisa Maria, Rode, Immanuel, Schrezenmeier, Hubert, Mytilineos, Joannis, Fürst, Daniel, Neuchel, Christine, Gowdavally, Sowmya, Tsamadou, Chrysanthi, Platzbecker, Uwe, Sala, Elisa, Wagner-Drouet, Eva, Valerius, Thomas, Kröger, Nicolaus, Wulf, Gerald, Einsele, Hermann, Thurner, Lorenz, Schaefer-Eckart, Kerstin, Freitag, Sebastian, Casper, Jochen, Dürholt, Mareike, Kaufmann, Martin, Hertenstein, Bernd, Klein, Stefan, Ringhoffer, Mark, Frank, Sandra, Amann, Elisa Maria, Rode, Immanuel, Schrezenmeier, Hubert, Mytilineos, Joannis, and Fürst, Daniel

Abstract

Graft-versus-host disease (GvHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and is highly influenced by the degree of HLA matching between recipient and donor. The HLA-class Ib molecule HLA-G has been shown to promote tolerogenicity through its interaction with inhibitory receptors found on several immunocompetent cells. We hypothesized that in an allo-HSCT setting, HLA-G mismatches may negatively impact the HLA-G-mediated tolerogenicity either due to inefficient interaction with the inhibitory receptors of the transplanted immune cells or due to direct allorecognition of mismatched HLA-G on host cells by the immune cells of the donor.

Published
2022

9. Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation

Author

Heyn, Jens Michael, Bräuninger, Susanne Barbara, Dimova-Dobreva, Miryana, Mathieson, Nicola, Koptelova, Natalia V., Kolpakova, Anna, Seidl, Christian, Reinhardt, Peter, Tsamadou, Chrysanthi, Schrezenmeier, Hubert, Nakov, Roumen, Seifried, Erhard, Bönig, Halvard-Björn, Heyn, Jens Michael, Bräuninger, Susanne Barbara, Dimova-Dobreva, Miryana, Mathieson, Nicola, Koptelova, Natalia V., Kolpakova, Anna, Seidl, Christian, Reinhardt, Peter, Tsamadou, Chrysanthi, Schrezenmeier, Hubert, Nakov, Roumen, Seifried, Erhard, and Bönig, Halvard-Björn

Abstract

Background: Safety, tolerability and efficacy of granulocyte colony-stimulating factor (G-CSF) for mobilization of hematopoietic stem and progenitor cells (HSPCs) from healthy donors have been conclusively demonstrated. This explicitly includes, albeit for smaller cohorts and shorter observation periods, biosimilar G-CSFs. HSPC donation is non-remunerated, its sole reward being “warm glow”, hence harm to donors must be avoided with maximal certitude. To ascertain, therefore, long-term physical and mental health effects of HSPC donation, a cohort of G-CSF mobilized donors was followed longitudinally. Methods: We enrolled 245 healthy volunteers in this bi-centric long-term surveillance study. 244 healthy volunteers began mobilization with twice-daily Sandoz biosimilar filgrastim and 242 underwent apheresis after G-CSF mobilization. Physical and mental health were followed up over a period of 5-years using the validated SF-12 health questionnaire. Results: Baseline physical and mental health of HSPC donors was markedly better than in a healthy reference population matched for ethnicity, sex and age. Physical, but not mental health was sharply diminished at the time of apheresis, likely due to side effects of biosimilar G-CSF, however had returned to pre-apheresis values by the next follow-up appointment after 6 months. Physical and mental health slightly deteriorated over time with kinetics reflecting the known effects of aging. Hence, superior physical and mental health compared to the general healthy non-donor population was maintained over time. Conclusions: HSPC donors are of better overall physical and mental health than the average healthy non-donor. Superior well-being is maintained over time, supporting the favorable risk–benefit assessment of volunteer HSPC donation. Trial registration National Clinical Trial NCT01766934

Published
2022

10. HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation

Author

Tsamadou, Chrysanthi, primary, Engelhardt, Daphne, additional, Platzbecker, Uwe, additional, Sala, Elisa, additional, Valerius, Thomas, additional, Wagner-Drouet, Eva, additional, Wulf, Gerald, additional, Kröger, Nicolaus, additional, Murawski, Niels, additional, Einsele, Hermann, additional, Schaefer-Eckart, Kerstin, additional, Freitag, Sebastian, additional, Casper, Jochen, additional, Kaufmann, Martin, additional, Dürholt, Mareike, additional, Hertenstein, Bernd, additional, Klein, Stefan, additional, Ringhoffer, Mark, additional, Frank, Sandra, additional, Neuchel, Christine, additional, Schrezenmeier, Hubert, additional, Mytilineos, Joannis, additional, and Fuerst, Daniel, additional

Published
2021
Full Text
View/download PDF

11. Erytra blood group analyser and kode technology testing of SARS‐CoV‐2 antibodies among convalescent patients and vaccinated individuals

Author

Weinstock, Christof, primary, Flegel, Willy A., additional, Srivastava, Kshitij, additional, Kaiser, Sabine, additional, Schrezenmeier, Hubert, additional, Tsamadou, Chrysanthi, additional, Ludwig, Carolin, additional, Jahrsdörfer, Bernd, additional, Bovin, Nicolai V., additional, and Henry, Stephen M., additional

Published
2021
Full Text
View/download PDF

12. Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT

Author

Tsamadou, Chrysanthi, primary, Gowdavally, Sowmya, additional, Platzbecker, Uwe, additional, Sala, Elisa, additional, Valerius, Thomas, additional, Wulf, Gerald, additional, Wagner, Eva Maria, additional, Kroeger, Nicolaus, additional, Murawski, Niels, additional, Einsele, Hermann, additional, Schaefer-Eckart, Kerstin, additional, Freitag, Sebastian, additional, Casper, Jochen, additional, Kaufmann, Martin, additional, Dürholt, Mareike, additional, Hertenstein, Bernd, additional, Klein, Stefan, additional, Ringhoffer, Mark, additional, Neuchel, Christine, additional, Rode, Immanuel, additional, Mytilineos, Joannis, additional, Schrezenmeier, Hubert, additional, and Fürst, Daniel, additional

Published
2021
Full Text
View/download PDF

13. mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects

Author

Fabricius, Dorit, primary, Ludwig, Carolin, additional, Scholz, Judith, additional, Rode, Immanuel, additional, Tsamadou, Chrysanthi, additional, Jacobsen, Eva-Maria, additional, Winkelmann, Martina, additional, Grempels, Aline, additional, Lotfi, Ramin, additional, Janda, Aleš, additional, Körper, Sixten, additional, Adler, Guido, additional, Debatin, Klaus-Michael, additional, Schrezenmeier, Hubert, additional, and Jahrsdörfer, Bernd, additional

Published
2021
Full Text
View/download PDF

15. HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation

Author

Tsamadou, Chrysanthi, Engelhardt, Daphne, Platzbecker, Uwe, Sala, Elisa, Valerius, Thomas, Wagner-Drouet, Eva, Wulf, Gerald, Kröger, Nicolaus, Murawski, Niels, Einsele, Herrmann, Schaefer-Eckart, Kerstin, Freitag, Sebastian, Caspar, Jochen, Kaufmann, Martin, Dürholt, Mareike, Herstenstein, Bernd, Klein, Stefan, Ringhoffer, Mark, Frank, Sandra, Neuchel, Christine, Schrezenmeier, Hubert, Mytilineos, Joannis, Fuerst, Daniel, Tsamadou, Chrysanthi, Engelhardt, Daphne, Platzbecker, Uwe, Sala, Elisa, Valerius, Thomas, Wagner-Drouet, Eva, Wulf, Gerald, Kröger, Nicolaus, Murawski, Niels, Einsele, Herrmann, Schaefer-Eckart, Kerstin, Freitag, Sebastian, Caspar, Jochen, Kaufmann, Martin, Dürholt, Mareike, Herstenstein, Bernd, Klein, Stefan, Ringhoffer, Mark, Frank, Sandra, Neuchel, Christine, Schrezenmeier, Hubert, Mytilineos, Joannis, and Fuerst, Daniel

Abstract

The HLA-DRB3/4/5 loci are closely linked to the HLA-DRB1 gene. Mismatches in these loci occur with a frequency of about 8%–12% in otherwise 10/10 HLA-matched transplant pairs. There is preliminary evidence that these disparities may associate with increased acute graft-versus-host disease (GvHD) rates. The aim of this study was to analyze a large cohort of German patients and their donors for HLA-DRB3/4/5 compatibility and to correlate the HLA-DRB3/4/5 matching status with the outcome of unrelated hematopoietic stem cell transplantation (uHSCT). To this end, 3,410 patients and their respective donors were HLA-DRB3/4/5 and HLA-DPB1 typed by amplicon-based nextgeneration sequencing (NGS). All patients included received their first allogeneic transplant for malignant hematologic diseases between 2000 and 2014. Mismatches in the antigen recognition domain (ARD) of HLA-DRB3/4/5 genes were correlated with clinical outcome. HLA-DRB3/4/5 incompatibility was seen in 12.5% (n = 296) and 17.8% (n = 185) of the 10/10 and 9/10 HLA-matched cases, respectively. HLA-DRB3/4/5 mismatches in the ARD associated with a worse overall survival (OS), as shown in univariate (5-year OS: 46.1% vs. 39.8%, log-rank p = 0.038) and multivariate analyses [hazard ratio (HR) 1.25, 95% CI 1.02–1.54, p = 0.034] in the otherwise 10/10 HLAmatched subgroup. The worse outcome was mainly driven by a significantly higher nonrelapse mortality (HR 1.35, 95% CI 1.05–1.73, p = 0.017). In the 9/10 HLA-matched cases, the effect was not statistically significant. Our study results suggest that mismatches within the ARD of HLA-DRB3/4/5 genes significantly impact the outcome of otherwise fully matched uHSCT and support their consideration upon donor selection in the future.

Published
2021

16. The role of HLA-E polymorphism in the outcome of unrelated hematopoietic stem cell transplantation : retrospective analysis of two large independent acute leukemia cohorts

Author

Tsamadou, Chrysanthi, Schrezenmeier, Hubert, and Bunjes, Donald

Subjects
Akute Leukämie, Matched unrelated HSCT, HLA-E, Hematopoietic stem cell transplantation, ddc:610, HLA antigens, Acute Leukemia, DDC 610 / Medicine & health, Periphere Stammzellentransplantation
Abstract

More than 50 years after its first implementation for the treatment of acute leukemia, allogeneic hematopoietic stem cell transplantation (HSCT) is still considered the only therapeutic option with life-long curative potential. Despite the undeniable progress made, HSCT remains a high risk treatment even in the optimal setting of 10/10 Human Leukocyte Antigen (HLA) compatibility between recipient and donor. In the search of immunogenetic factors beyond classical HLA antigens possibly impacting HSCT outcome, a limited number of studies have investigated the role of HLA-E in HSCT outcome. HLA-E is a ubiquitously transcribed, non-classical Major Histocompatibility Complex (MHC) Ib molecule with a multifaceted yet not fully understood role in both innate and adaptive immunity. Aim of this study was to investigate for the first time on such a large scale the effect of HLA-E polymorphism on HSCT outcome in a 10/10 HLA matched unrelated acute leukemia setting analyzing data from two large independent cohorts. The two cohorts (German cohort n=509, CIBMTR (Center for International Blood and Marrow Transplant Research) cohort n=1840) analyzed within this study consisted of adult acute leukemia patients receiving their first 10/10 HLA matched unrelated graft between 2000 and 2015. Both recipients and donors were HLA-E genotyped by Sanger and Next Generation Sequencing (NGS) using in-house kits in our laboratory in Ulm. Overall survival (OS), disease free survival (DFS), relapse (RI), transplant-related mortality (TRM), acute GvHD (aGvHD) and chronic GvHD (cGvHD) were evaluated; p32%) observed in both cohorts were in accordance with previously reported data. Regarding the effect of HLA-E polymorphism on HSCT outcome, the German cohort analysis revealed a significant correlation between HLA-E mismatch and improved HSCT outcome mainly in advanced disease patients. Specifically, patients transplanted by HLA-E mismatched donors exhibited significantly better OS and DFS rates due to lower TRM. The CIBMTR cohort analysis did not confirm this favorable effect, as HLA-E match status between recipient and donor did not have any impact on any outcome endpoint. With respect to the effect of recipient and/or donor HLA-E genotype on HSCT outcome, both cohort analyses identified the HLA-E*01:03/01:03 as an unfavorable prognostic factor. The results of the CIBMTR analysis as to this finding were significantly more enlightening indicating that the HLA-E*01:03/01:03 negative effect is mainly donor driven, with the patient HLA-E genotype effect being only weakly synergistic. Specifically, donor HLA-E*01:03/01:03 genotype was found to associate with significantly lower DFS, apparently due to higher relapse incidence rate. This study is the largest to date investigating the effect of HLA-E polymorphism on HSCT outcome. The main conclusions drawn are that: HLA-E matching between patients and donors in the setting of unrelated HSCT for acute leukemia confers no advantage to outcome; HLA-E incompatibility between patients and donors may improve unrelated HSCT outcome in a subset of advanced disease patients receiving anti-thymocyte globulin and; avoidance of HLA-E*01:03/01:03 donors may improve DFS prognostics in patients in complete remission undergoing first matched unrelated HSCT for acute leukemia. Although no definitive conclusions can be drawn before molecular-based studies shed light on the mechanisms implicated, these observations certainly set the basis for future consideration of HLA-E as relevant clinical prognostic factor in a matched unrelated HSCT setting for acute leukemia patients.

Published
2020

17. Peripheral cytokine levels differ by HPV status and change treatment-dependently in patients with head and neck squamous cell carcinoma

Author

Mytilineos, Daphne Ariadne, Esic, Jasmin, Witzleben, Adrian Job Merlin von, Mytilineos, Joannis, Lotfi, Ramin, Fürst, Daniel, Tsamadou, Chrysanthi, Theodoraki, Marie-Nicole, Oster, Angelika, Völkel, Gunnar, Kestler, Hans A., Brunner, Cornelia, Schuler, Patrick, Doescher, Johannes, Hoffmann, Thomas K., and Laban, Simon Andreas

Subjects
Male, Tumor escape, chemical and pharmacologic phenomena, Alphapapillomavirus, Head and neck neoplasms, Granzymes, Article, lcsh:Chemistry, Humans, Perforine, Prospective Studies, fas Receptor, ddc:610, HMGB1 Protein, Humanes Papillomavirus, lcsh:QH301-705.5, Cytokine, Aged, Cancer, Human papillomavirus (HPV), Inflammation, Squamous Cell Carcinoma of Head and Neck, Perforin, Longitudinal studies, Entzündung, Papillomavirus Infections, Lymphocytes, Tumor-infiltrating, longitudinal study, Chemoradiotherapy, Middle Aged, Fas, lcsh:Biology (General), lcsh:QD1-999, Cytokines, Female, head and neck cancer, High-Mobility-Group-Protein B1(HMGB1), Tumor immune evasion, Neoplasm Recurrence, Local, DDC 610 / Medicine & health
Abstract

Cytokines and immune mediators play an important role in the communication between immune cells guiding their response to infectious diseases or cancer. In this study, a comprehensive longitudinal analysis of serum cytokines and immune mediators in head and neck squamous cell carcinoma (HNSCC) patients was performed. In a prospective, non-interventional, longitudinal study, blood samples from 22 HNSCC patients were taken at defined time points (TP) before, during, and every 3 months after completion of (chemo)radio)therapy (CRT/RT) until 12 months after treatment. Serum concentrations of 17 cytokines/immune mediators and High-Mobility-Group-Protein B1 (HMGB1) were measured by fluorescent bead array and ELISA. Concentrations of sFas were significantly elevated during and after CRT/RT, whereas perforin levels were significantly decreased after CRT/RT. Levels of MIP-1&beta, and Granzyme B differed significantly during CRT/RT by HPV status. Increased HMGB1 levels were observed at recurrence, accompanied by high levels of IL-4 and IL-10. The sFas increase and simultaneous perforin decrease may indicate an impaired immune cell function during adjuvant radiotherapy. Increased levels of pro-inflammatory cytokines in HPV+ compared to HPV&minus, patients seem to reflect the elevated immunogenicity of HPV-positive tumors. High levels of HMGB1 and anti-inflammatory cytokines at recurrence may be interpreted as a sign of immune evasion.

Published
2020

18. The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis

Author

Mytilineos, Daphne, primary, Tsamadou, Chrysanthi, additional, Neuchel, Christine, additional, Platzbecker, Uwe, additional, Bunjes, Donald, additional, Schub, Natalie, additional, Wagner-Drouet, Eva, additional, Wulf, Gerald, additional, Kröger, Nicolaus, additional, Murawski, Niels, additional, Einsele, Hermann, additional, Schaefer-Eckart, Kerstin, additional, Freitag, Sebastian, additional, Casper, Jochen, additional, Kaufmann, Martin, additional, Dürholt, Mareike, additional, Hertenstein, Bernd, additional, Klein, Stefan, additional, Ringhoffer, Mark, additional, Mueller, Carlheinz R., additional, Frank, Sandra, additional, Schrezenmeier, Hubert, additional, Fuerst, Daniel, additional, and Mytilineos, Joannis, additional

Published
2021
Full Text
View/download PDF

19. Peripheral Cytokine Levels Differ by HPV Status and Change Treatment-Dependently in Patients with Head and Neck Squamous Cell Carcinoma

Author

Mytilineos, Daphne, primary, Ezić, Jasmin, additional, von Witzleben, Adrian, additional, Mytilineos, Joannis, additional, Lotfi, Ramin, additional, Fürst, Daniel, additional, Tsamadou, Chrysanthi, additional, Theodoraki, Marie-Nicole, additional, Oster, Angelika, additional, Völkel, Gunnar, additional, Kestler, Hans A., additional, Brunner, Cornelia, additional, Schuler, Patrick J., additional, Doescher, Johannes, additional, Hoffmann, Thomas K., additional, and Laban, Simon, additional

Published
2020
Full Text
View/download PDF

22. HLA‐DRB4*01:14 is a null allele, and renamed HLA‐DRB4*01:14N

Author

Fuerst, Daniel, Tsamadou, Chrysanthi, Gowdavally, Sowmya, Schrezenmeier, Hubert, and Mytilineos, Joannis

Subjects
HLA, null allele, ddc:610, HLA-DRB4 chains, DDC 610 / Medicine & health, HLA-DRB4
Abstract

Full���length sequencing of HLA���DRB4*01:14 showed the same splice site mutation as in HLA���DRB4*01:03:01:02N., publishedVersion

Published
2019

25. Next-Generation Sequencing Technologies in Blood Group Typing.

Author

Fürst, Daniel, Tsamadou, Chrysanthi, Neuchel, Christine, Schrezenmeier, Hubert, Mytilineos, Joannis, and Weinstock, Christof

Subjects
*BLOOD grouping & crossmatching, *BLOOD group antigens, *NUCLEOTIDE sequencing, *HUMAN genome, *GROUP technology
Abstract

Sequencing of the human genome has led to the definition of the genes for most of the relevant blood group systems, and the polymorphisms responsible for most of the clinically relevant blood group antigens are characterized. Molecular blood group typing is used in situations where erythrocytes are not available or where serological testing was inconclusive or not possible due to the lack of antisera. Also, molecular testing may be more cost-effective in certain situations. Molecular typing approaches are mostly based on either PCR with specific primers, DNA hybridization, or DNA sequencing. Particularly the transition of sequencing techniques from Sanger-based sequencing to next-generation sequencing (NGS) technologies has led to exciting new possibilities in blood group genotyping. We describe briefly the currently available NGS platforms and their specifications, depict the genetic background of blood group polymorphisms, and discuss applications for NGS approaches in immunohematology. As an example, we delineate a protocol for large-scale donor blood group screening established and in use at our institution. Furthermore, we discuss technical challenges and limitations as well as the prospect for future developments, including long-read sequencing technologies. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

26. The Role of HLA-E Polymorphism in Acute Leukemia Patients Receiving a 10/10 HLA Matched Unrelated HSCT

Author

Tsamadou, Chrysanthi, primary, Wang, Tao, additional, Fürst, Daniel, additional, Lee, Stephanie J., additional, Spellman, Stephen R., additional, Fleischhauer, Katharina, additional, Hsu, Katharine C., additional, Paczesny, Sophie, additional, Verneris, Michael R, additional, Neuchel, Christine, additional, Schrezenmeier, Hubert, additional, and Mytilineos, Joannis, additional

Published
2018
Full Text
View/download PDF

27. OR26. Investigating the impact of patient’s non-shared HLA-C Allotype expression levels in A 9/10 Single HLA-C mismatched hematopoieticstem cell transplantationsetting using two different HLA-C Expression proxy models

Author

Tsamadou, Chrysanthi, primary, Fürst, Daniel, additional, Rojewski, Markus, additional, Niederwieser, Dietger, additional, Bunjes, Donald, additional, Neuchel, Christine, additional, Gramatzki, Martin, additional, Arnold, Renate, additional, Wagner, Eva, additional, Einsele, Hermann, additional, Körper, Sixten, additional, Schrezenmeier, Hubert, additional, and Mytilineos, Joannis, additional

Published
2018
Full Text
View/download PDF

28. Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects

Author

Fuerst, Daniel, primary, Frank, Sandra, additional, Mueller, Carlheinz, additional, Beelen, Dietrich W, additional, Schetelig, Johannes, additional, Niederwieser, Dietger, additional, Finke, Jürgen, additional, Bunjes, Donald, additional, Kröger, Nicolaus, additional, Neuchel, Christine, additional, Tsamadou, Chrysanthi, additional, Schrezenmeier, Hubert, additional, Beyersmann, Jan, additional, and Mytilineos, Joannis, additional

Published
2018
Full Text
View/download PDF

29. Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients

Author

Tsamadou, Chrysanthi, primary, Fürst, Daniel, additional, Vucinic, Vladan, additional, Bunjes, Donald, additional, Neuchel, Christine, additional, Mytilineos, Daphne, additional, Gramatzki, Martin, additional, Arnold, Renate, additional, Wagner, Eva Maria, additional, Einsele, Hermann, additional, Müller, Carlheinz, additional, Schrezenmeier, Hubert, additional, and Mytilineos, Joannis, additional

Published
2017
Full Text
View/download PDF

30. P043 HLA-DPB matching and donor cytomegalovirus positive (CMV+) status: An “unconventional alliance” associated with a decreased relapse incidence in unrelated hematopoietic stem cell transplantation (UHSCT)

Author

Mytilineos, Daphne, primary, Fuerst, Daniel, additional, Niederwieser, Dietger, additional, Neuchel, Christine, additional, Bunjes, Donald, additional, Tsamadou, Chrysanthi, additional, Gramatzki, Martin, additional, Einsele, Hermann, additional, Wagner, Eva M., additional, Stuhler, Gernot, additional, Arnold, Renate, additional, Wulf, Gerald, additional, Pfreundschuh, Michael, additional, Schrezenmeier, Hubert, additional, and Mytilineos, Joannis, additional

Published
2017
Full Text
View/download PDF

32. Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors—A Retrospective Study

Author

Neuchel, Christine, primary, Fürst, Daniel, additional, Niederwieser, Dietger, additional, Bunjes, Donald, additional, Tsamadou, Chrysanthi, additional, Wulf, Gerald, additional, Pfreundschuh, Michael, additional, Wagner, Eva, additional, Stuhler, Gernot, additional, Einsele, Hermann, additional, Schrezenmeier, Hubert, additional, and Mytilineos, Joannis, additional

Published
2017
Full Text
View/download PDF

34. HLA Matching in Hematopoietic Stem Cell Transplantation: Where Do We Stand?

Author

Tsamadou, Chrysanthi

Subjects
*HEMATOPOIETIC stem cell transplantation, *HLA histocompatibility antigens, *DRUG development
Abstract

Despite the undeniable progress in the development of new effective drugs against malignant and non-malignant hematological diseases, allogeneic hematopoietic stem cell transplantation (HSCT) remains the only therapeutic option with long lasting curative potential. Continuous research for the last fifty years has repeatedly shown that human leukocyte antigen (HLA) compatibility between recipient and donor constitutes the most decisive factor for successful engraftment and higher rates of overall survival. Unfortunately, a fully HLA matched donor is in many cases precluded, therefore the identification of better tolerated HLA mismatches has always been and still remains an important research objective. In this review we recapitulate current knowledge on how HLA- (i.e. locus, resolution level, directionality, number etc.) as well as non-HLA factors (i.e. disease stage, recipient age, graft source etc.) may impact the overall effect of HLA incompatibility on HSCT outcome, with the aim to offer an overview on potentially "permissive" HLA mismatches. [ABSTRACT FROM AUTHOR]

Published
2019

35. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte‐colony‐stimulating factor: safety, efficacy, and graft performance

Author

Becker, Petra, primary, Schwebig, Arnd, additional, Brauninger, Susanne, additional, Bialleck, Heike, additional, Luxembourg, Beate, additional, Schulz, Miriam, additional, Tsamadou, Chrysanthi, additional, Wiesneth, Markus, additional, Reinhardt, Peter, additional, Mytilineos, Joannis, additional, Seidl, Christian, additional, Gattu, Sreekanth, additional, Kaliakina, Natalia, additional, Singh, Pritibha, additional, Schrezenmeier, Hubert, additional, Seifried, Erhard, additional, and Bonig, Halvard, additional

Published
2016
Full Text
View/download PDF

36. P046 Deconstructing HLA-C mismatch in hematopoietic stem cell transplantation

Author

Tsamadou, Chrysanthi, primary, Fürst, Daniel, additional, Niederwieser, Dietger, additional, Bunjes, Donald, additional, Neuchel, Christine, additional, Gramatzki, Martin, additional, Arnold, Renate, additional, Wagner, Eva, additional, Einsele, Hermann, additional, Schrezenmeier, Hubert, additional, and Mytilineos, Joannis, additional

Published
2016
Full Text
View/download PDF

39. Erytra Blood Group Analyser and Kode Technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals.

Author

Weinstock C, Flegel WA, Srivastava K, Kaiser S, Schrezenmeier H, Tsamadou C, Ludwig C, Jahrsdörfer B, Bovin NV, and Henry SM

Abstract

Surveillance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires tests to monitor antibody formation and prevalence. We detected SARS-CoV-2 antibodies using red cells coated by Kode technology with short peptides derived from the SARS-CoV-2 spike protein. Such modified red cells, called C19-kodecytes, can be used as reagent cells in any manual or automated column agglutination assay. We investigated the presence of SARS-CoV-2 antibodies in 130 samples from COVID-19 convalescent plasma donors using standard manual technique, two FDA authorized ELISA assays and a virus neutralisation assay. The sensitivity of the C19-kodecyte assay was 88%, comparable to the anti-SP and anti-NCP ELISAs (86% and 83%) and the virus neutralisation assay (88%). The specificity of the C19-kodecyte assay was 90% (anti-SP 100% and anti-NCP 97%). Likewise, 231 samples from 73 vaccinated individuals were tested with an automated analyser and we monitored the appearance and persistence of SARS-CoV-2 antibodies. The C19-kodecyte assay is a robust tool for SARS-CoV-2 antibody detection. Automated blood group analyser use enables large-scale SARS-CoV-2 antibody testing for vaccination monitoring in population surveys.

Published
2021
Full Text
View/download PDF

40. Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.

Author

Fuerst D, Mueller C, Beelen DW, Neuchel C, Tsamadou C, Schrezenmeier H, and Mytilineos J

Subjects
Adolescent, Adult, Aged, Antineoplastic Agents therapeutic use, Female, Germany, Graft vs Host Disease diagnosis, Graft vs Host Disease mortality, Graft vs Host Disease pathology, Graft vs Host Disease prevention & control, Humans, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Lymphoma, Non-Hodgkin mortality, Lymphoma, Non-Hodgkin pathology, Lymphoma, Non-Hodgkin therapy, Male, Middle Aged, Myelodysplastic Syndromes mortality, Myelodysplastic Syndromes pathology, Myelodysplastic Syndromes therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk, Time Factors, Transplantation, Homologous, Unrelated Donors, Hematopoietic Stem Cell Transplantation methods, Leukemia, Myeloid, Acute diagnosis, Lymphoma, Non-Hodgkin diagnosis, Myelodysplastic Syndromes diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Registries, Transplantation Conditioning methods
Abstract

Hematopoietic stem cell transplantation is a multifactorial process. Some of the predictors exhibit time-dependent effects. We present a systematic analysis and description of selected clinical predictors influencing outcome in a time-dependent manner based on an analysis of registry data from the German Registry for Stem Cell Transplantation. A total of 14,951 patients with acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome and non-Hodgkin lymphoma transplanted with peripheral blood stem cells or bone marrow grafts were included. Multivariate Cox regression models were tested for time-dependent effects within each diagnosis group. Predictors not satisfying the proportional hazards assumption were modeled in a time-dependent manner, extending the Cox regression models. Similar patterns occurred in all diagnosis groups. Patients with a poor Karnofsky performance score (<80) had a high risk for early mortality until day 139 following transplantation (HR 2.42, CI: 2.19-2.68; P<0.001) compared to patients with a good Karnofsky performance score (80-100). Afterwards the risk reduced to HR 1.43, CI: 1.25-1.63; P<0.001. A lower mortality risk was found for patients after conditioning treatment with reduced intensity until day 120 post transplant (HR: 0.81 CI: 0.75-0.88; P<0.001). After this, a slightly higher risk could be shown for these patients. Similarly, patients who had received a PBSC graft exhibited a significantly lower mortality risk until day 388 post transplantation (HR 0.79, CI: 0.73-0.85; P<0.001), reversing to a significantly higher risk afterwards (HR 1.23, CI: 1.08-1.40; P=0.002). Integrating time dependency in regression models allows a more accurate description and quantification of clinical predictors to be made, which may help in risk assessment and patient counseling., (Copyright© Ferrata Storti Foundation.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results